New NLRP3 Inhibitor Slashes Inflammation Markers by 85% in Phase 1 Trial
BioAge's oral drug BGE-102 dramatically reduced hsCRP and IL-6 in obese participants with elevated inflammation, with a strong safety profile.
Summary
BioAge has released promising Phase 1 results for BGE-102, an oral drug that targets the NLRP3 inflammasome — a key driver of chronic inflammation linked to aging and disease. In a randomized, placebo-controlled trial involving healthy volunteers and people with obesity and elevated inflammation, the drug reduced high-sensitivity C-reactive protein (hsCRP) by up to 86% within weeks. Over 87% of participants on the lower dose normalized their hsCRP levels to healthy ranges. IL-6 and fibrinogen, two other inflammation markers tied to cardiovascular and metabolic risk, also declined. The drug was well tolerated with no serious adverse events. Phase 2 trials targeting cardiovascular risk and diabetic eye disease are planned for mid-2026.
Detailed Summary
Chronic low-grade inflammation — sometimes called 'inflammaging' — is one of the most well-established drivers of accelerated aging, cardiovascular disease, metabolic dysfunction, and neurodegeneration. Targeting the NLRP3 inflammasome, a molecular complex that triggers inflammatory cascades, has become a major focus in longevity-oriented drug development. BioAge's BGE-102 is one of the most advanced oral candidates in this space.
In a randomized, double-blind, placebo-controlled Phase 1 trial, BGE-102 was tested at two doses — 60 mg once daily for 21 days and 120 mg once daily for 14 days — in healthy volunteers and participants with obesity and elevated baseline inflammation. Both doses produced rapid, large reductions in hsCRP, a widely used biomarker of systemic inflammation. The 60 mg group saw median reductions of 85% by day 7, reaching 86% by day 21, with 87% of treated participants achieving hsCRP below 2 mg/L — a clinically meaningful threshold. The 120 mg group showed comparable results, with 93% normalizing hsCRP by day 14.
Beyond hsCRP, reductions were also observed in IL-6 and fibrinogen — inflammatory proteins independently associated with cardiovascular and metabolic risk. These multi-marker improvements suggest BGE-102 may be addressing upstream inflammatory signaling rather than a single downstream marker.
Safety data were encouraging. Adverse events were mild to moderate, with no serious events, no discontinuations, and no meaningful changes in cardiac or laboratory measures. The drug's brain-penetrant design also raises potential relevance for neuroinflammation, though this was not a primary endpoint here.
Caveats remain significant. Phase 1 trials are designed primarily for safety and dosing, not efficacy. Participant numbers were small, and long-term effects are unknown. Phase 2 cardiovascular and diabetic macular edema trials planned for mid-2026 will be critical for validating whether these biomarker improvements translate to meaningful clinical outcomes.
Key Findings
- BGE-102 at 60 mg reduced hsCRP by up to 86% over 21 days in participants with elevated inflammation.
- 87–93% of treated participants normalized hsCRP below 2 mg/L, a clinically meaningful cardiovascular threshold.
- IL-6 and fibrinogen — key inflammatory risk markers — also declined alongside hsCRP.
- No serious adverse events, discontinuations, or significant safety signals were reported across dose levels.
- Phase 2 cardiovascular proof-of-concept trial planned for mid-2026 will test real-world clinical impact.
Methodology
This is a news report summarizing company-disclosed Phase 1 clinical trial results. The trial was randomized, double-blind, and placebo-controlled, lending methodological credibility, but data come from a press release rather than a peer-reviewed publication. Independent verification of the full dataset has not yet occurred.
Study Limitations
Phase 1 trials are primarily safety studies with small sample sizes; efficacy conclusions cannot yet be drawn. Data were released via company announcement, not peer-reviewed publication, so independent scrutiny is pending. Long-term effects, durability of inflammation reduction, and clinical outcome benefits remain unproven.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.